Study: Marijuana compound helps mitigate cocaine addiction in mice

By Stephen C. Webster
Tuesday, July 26, 2011 12:28 EDT
google plus icon
  • Print Friendly and PDF
  • Email this page

Researchers in Maryland and Beijing have learned that a component marijuana helps mitigate cocaine addiction in mice, leading some to hope that marijuana may one day become the next big anti-addiction therapy.

The discovery was announced in the July 2011 edition of Nature Neuroscience.

The study found that cannabidiol, an active component of marijuana that does not produce an inebriating effect, effectively turns down a receptor in the brain that is stimulated by cocaine.

Scientists used a synthetic version of cannabidiol, called JWH-133, to see how mice given regular doses of cocaine would respond. They found that mice given JWH-133 dramatically reduced their cocaine intake by up to 60 percent.

Their success in reducing cocaine consumption in mice may lead to new drug replacement therapies for cocaine and crack addiction, helping addicts detox and overcome withdrawal symptoms much like methadone therapy sometimes prescribed to heroin addicts.

As a recreational drug, marijuana produces less dependence and withdrawal effects than even caffeine. Cocaine is much more intoxicating and produces a strong reinforcing effect that makes a user more likely to use the drug again.

JWH-133 is closely related to JWH-018, which has been the subject of recent controversy for its appearance in “Spice” and other herbal smoking blends purported to produce marijuana-like highs. While JWH-133 does not produce such effects, JWH-018 and other similar test chemicals do, leading the Drug Enforcement Administration to place a series of them on their list of controlled substances.

The International Narcotics Control Board, an independent agency set up by the United Nations, said recently that banning JWH-018 was a positive step in drug control efforts, but urged industrialized nations to go further and also adopt blanket bans on new substances to prevent the rise of new designer drugs — a policy recommendation that, if adopted, would also apply to JWH-133.

(H/T: Time)

Stephen C. Webster
Stephen C. Webster
Stephen C. Webster is the senior editor of Raw Story, and is based out of Austin, Texas. He previously worked as the associate editor of The Lone Star Iconoclast in Crawford, Texas, where he covered state politics and the peace movement’s resurgence at the start of the Iraq war. Webster has also contributed to publications such as True/Slant, Austin Monthly, The Dallas Business Journal, The Dallas Morning News, Fort Worth Weekly, The News Connection and others. Follow him on Twitter at @StephenCWebster.
By commenting, you agree to our terms of service
and to abide by our commenting policy.